Adrienne Hammill MD

Dr. Adrienne Hammill MD

orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2016 in Pediatrics
Verified
Journal Article
Open access
PDF file
DADenise M. Adams
Denise M. Adams
CTCameron C. Trenor
Cameron C. Trenor
AMAdrienne Hammill MD
Adrienne Hammill MD
AVAlexander A. Vinks
Alexander A. Vinks
MPManish N. Patel
Manish N. Patel
RARichard G. Azizkhan
Richard G. Azizkhan
BACKGROUND AND OBJECTIVES: Complicated vascular anomalies have limited therapeutic options and cause significant morbidity and mortality. This Phase II trial enrolled patients with complicated vascular anomalies to determine the efficacy and safety of treatment with sirolimus for 12 courses; each course was defined as 28 days. METHODS: Treatment consisted of a continuous dosing schedule of oral sirolimus starting at 0.8 mg/m2 per dose twice daily, with pharmacokinetic-guided target serum trough levels of 10 to 15 ng/mL. The primary outcomes were responsiveness to sirolimus by the end of course 6 (evaluated according to functional impairment score, quality of life, and radiologic assessment) and the incidence of toxicities and/or infection-related deaths. RESULTS: Sixty-one patients were enrolled; 57 patients were evaluable for efficacy at the end of course 6, and 53 were evaluable at the end of course 12. No patient had a complete response at the end of course 6 or 12 as anticipated. At the end of course 6, a total of 47 patients had a partial response, 3 patients had stable disease, and 7 patients had progressive disease. Two patients were taken off of study medicine secondary to persistent adverse effects. Grade 3 and higher toxicities attributable to sirolimus included blood/bone marrow toxicity in 27% of patients, gastrointestinal toxicity in 3%, and metabolic/laboratory toxicity in 3%. No toxicity-related deaths occurred. CONCLUSIONS: Sirolimus was efficacious and well tolerated in these study patients with complicated vascular anomalies. Clinical activity was reported in the majority of the disorders.

28 March 2011 in Pediatric Blood & Cancer
Verified
Journal Article
Open access
PDF file
AMAdrienne Hammill MD
Adrienne Hammill MD
MWMarySue Wentzel
MarySue Wentzel
AGAnita Gupta
Anita Gupta
SNStephen Nelson
Stephen Nelson
ALAnne Lucky
Anne Lucky
DADenise M. Adams
Denise M. Adams
Background: Vascular anomalies comprise a diverse group of diagnoses. While infantile hemangiomas are common, the majority of these conditions are quite rare and have not been widely studied. Some of these lesions, though benign, can impair vital structures, be deforming, or even become life‐threatening. Vascular tumors such as kaposiform hemangioendotheliomas (KHE) and complicated vascular malformations have proven particularly difficult to treat.Procedure: Here we retrospectively evaluate a series of six patients with complicated, life‐threatening vascular anomalies who were treated with the mTOR inhibitor sirolimus for compassionate use at two centers after failing multiple other therapies.Results: These patients showed significant improvement in clinical status with tolerable side effects.Conclusions: Sirolimus appears to be effective and safe in patients with life‐threatening vascular anomalies and represents an important tool in treating these diseases. These findings are currently being further evaluated in a Phase II safety and efficacy trial. Pediatr Blood Cancer 2011; 57: 1018–1024.

15 December 2020 in Annals of Internal Medicine
Verified
Journal Article
Open access
MFMd Marie E. Faughnan
Md Marie E. Faughnan
JMJohannes J. Mager
Johannes J. Mager
SHSteven W. Hetts
Steven W. Hetts
VPValerie A. Palda
Valerie A. Palda
KLKelly Lang-Robertson
Kelly Lang-Robertson
RZRoberto Zarrabeitia
Roberto Zarrabeitia
Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant disease affecting multiple organ systems. The Second International HHT Guidelines provide evidence-informed consensus guidelines... Description: Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant disease with an estimated prevalence of 1 in 5000 that is characterized by the presence of vascular malformations (...

1 July 2013 in The Journal of Pediatrics
Verified
Journal Article
Closed access
BDBeth A. Drolet
Beth A. Drolet
CTCameron C. Trenor
Cameron C. Trenor
LBLeonardo R. Brandão
Leonardo R. Brandão
YCYvonne E. Chiu
Yvonne E. Chiu
RCRobert H. Chun
Robert H. Chun
DADenise M. Adams
Denise M. Adams

1 August 1999 in Experimental Cell Research
Verified
Journal Article
Closed access
AMAdrienne Hammill MD
Adrienne Hammill MD
JUJonathan W. Uhr
Jonathan W. Uhr
RSRichard Scheuermann
Richard Scheuermann

1 December 2018 in The Journal of Pediatrics
Verified
Journal Article
Closed access
IIIonela Iacobas
Ionela Iacobas
TPThuy L. Phung
Thuy L. Phung
DADenise M. Adams
Denise M. Adams
CTCameron C. Trenor
Cameron C. Trenor
FBFrancine Blei
Francine Blei
SFSteven J. Fishman
Steven J. Fishman